Google
NGNE 株価分析 — Neurogene Inc (Healthcare >> Biotechnology)
NGNE に関するよくある質問
NGNEのROE（自己資本利益率）は？
Neurogene IncのROEは-41.48%です。
NGNEの配当利回りは？
Neurogene Incの配当利回りは0.00%です。
NGNEの品質スコア（Quality Score）は？
当社のAIはNGNEの総合財務品質を100点中0点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
NGNEは今が買い時ですか？
当社AIのタイミングスコアは100点中67点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
NGNEはどのセクターに属しますか？
Neurogene IncはHealthcare >> Biotechnologyセクターに分類されます（NASDAQ市場）
NGNE AI Analysis Summary
Our AI summary for NGNE: Neurogene Inc (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -41.48%, a dividend yield of 0.00%. Its financial Quality Score stands at 0/100 — fundamentals below the market average. The AI Timing Score is 67/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 34.41
Price
1.54
(4.69%)
Day Change
|
|
|---|
NGNE, ファンダメンタルスコアはnot good ( ファンダメンタル = 0) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
ROEの伸びが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
ROEが昨年度比で低い
ROAがROEに比べて低い
ROAの伸びが低い
Last-year ROA is lower than last-2-years ROA.
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not quite good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 89 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 34.41 |
| PBV / Sector |
2.76 / 44,022.72
|
| Earning Per Share | -5.18 |
| PE / Sector |
N/A / 19.17
|
| PEG or PE/Growth / Sector |
N/A / 1.24
|
| Average 1M Daily Value |
8.34 M
|
| Average 1W Daily Value |
4.59 M
GREAT
|
| Timing Factors |
|
71% |
| Financial Health |
|
50% |
| ポイントになる統計 |
|
43% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-05 08:00:35 |
| Symbol | NGNE |
| Name | NEUROGENE INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 19.95 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 655.77 / 9,586.08 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 535 W 24th Street, New York, NY, United States, 10011
Phone: 855 508 3568
Website: https://www.neurogene.com
Employees: 131
Sector: Healthcare >> Biotechnology
Description: Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
